What is OS THERAPIES INCORPORATED's earnings per share (EPS)?

OS THERAPIES INCORPORATED (OSTX) reported diluted earnings per share of $-0.98 for fiscal year 2025. This represents a -11.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

OS THERAPIES INCORPORATED Financials

OSTX

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows OS THERAPIES INCORPORATED (OSTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

OS THERAPIES INCORPORATED passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.50x

For every $1 of reported earnings, OS THERAPIES INCORPORATED generates $0.50 in operating cash flow (-$14.2M OCF vs -$28.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-14.0x

OS THERAPIES INCORPORATED earns $-14.0 in operating income for every $1 of interest expense (-$28.7M vs $2.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$28.3M

YoY-316.1%

OS THERAPIES INCORPORATED's EBITDA was -$28.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 316.1% from the prior year.

Net Income

-$28.8M

YoY-223.7%

OS THERAPIES INCORPORATED reported -$28.8M in net income in fiscal year 2025. This represents a decrease of 223.7% from the prior year.

EPS (Diluted)

$-0.98

YoY-11.4%

OS THERAPIES INCORPORATED earned $-0.98 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 11.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$14.7M

OS THERAPIES INCORPORATED generated -$14.7M in free cash flow in fiscal year 2025, representing cash available after capex.

Cash & Debt

$5.5M

YoY+0.0%

OS THERAPIES INCORPORATED held $5.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

40M

YoY+89.4%

OS THERAPIES INCORPORATED had 40M shares outstanding in fiscal year 2025. This represents an increase of 89.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$16.4M

YoY+476.3%

OS THERAPIES INCORPORATED invested $16.4M in research and development in fiscal year 2025. This represents an increase of 476.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$466K

OS THERAPIES INCORPORATED invested $466K in capex in fiscal year 2025, funding long-term assets and infrastructure.

OSTX Income Statement

Metric	FY25	FY24	FY23
Revenue	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	$16.4M+476.3%	$2.8M-11.7%	$3.2M
SG&A Expenses	$12.3M+210.6%	$4.0M+253.1%	$1.1M
Operating Income	-$28.7M-321.3%	-$6.8M-56.9%	-$4.3M
Interest Expense	$2.1M0.0%	$2.1M-40.5%	$3.4M
Income Tax	N/A	N/A	N/A
Net Income	-$28.8M-223.7%	-$8.9M-14.0%	-$7.8M
EPS (Diluted)	$-0.98-11.4%	$-0.88	$-1.46

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.8M+50.2%	$2.5M+90.9%	$1.3M	N/A	$1.2M+205.2%	$397K+9.6%	$362K	N/A
SG&A Expenses	$3.1M+33.6%	$2.3M-36.6%	$3.7M	N/A	$1.2M+220.2%	$383K+42.8%	$268K	N/A
Operating Income	-$6.9M-42.2%	-$4.8M+3.2%	-$5.0M	N/A	-$2.4M-212.6%	-$780K-23.7%	-$630K	N/A
Interest Expense	N/A	N/A	N/A	N/A	$438K-43.7%	$778K-6.2%	$829K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.9M-51.6%	-$4.5M-17.0%	-$3.9M	N/A	-$2.9M-84.6%	-$1.6M-6.8%	-$1.5M	N/A
EPS (Diluted)	$-0.21-10.5%	$-0.19-5.6%	$-0.18	N/A	$-0.18+30.8%	$-0.26-4.0%	$-0.25	N/A

OSTX Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$6.8M+23.5%	$5.5M+594.0%	$798K
Current Assets	$333K-94.0%	$5.5M+600.4%	$790K
Cash & Equivalents	$5.5M0.0%	$5.5M+14095.1%	$39K
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$11.9M+34.7%	$8.8M-64.5%	$24.8M
Current Liabilities	$11.8M+154.2%	$4.6M-81.3%	$24.7M
Long-Term Debt	N/A	N/A	N/A
Total Equity	-$6.1M-86.6%	-$3.3M+86.4%	-$24.0M
Retained Earnings	-$67.2M-74.8%	-$38.4M-30.2%	-$29.5M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$9.0M-13.2%	$10.3M+142.6%	$4.2M-23.3%	$5.5M+180.1%	$2.0M+47.3%	$1.3M+28.0%	$1.0M+31.4%	$798K
Current Assets	$2.3M-34.7%	$3.6M-13.2%	$4.1M-26.0%	$5.5M+180.8%	$2.0M+47.5%	$1.3M+28.2%	$1.0M+31.8%	$790K
Cash & Equivalents	$1.9M-33.0%	$2.8M-5.7%	$3.0M-46.3%	$5.5M+197.8%	$1.9M+1857.4%	$95K-5.3%	$100K+157.1%	$39K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.2M+19.3%	$3.6M-57.8%	$8.4M-4.2%	$8.8M+228.0%	$2.7M-90.5%	$28.4M+7.0%	$26.6M+7.0%	$24.8M
Current Liabilities	$4.1M+19.9%	$3.5M-2.2%	$3.5M-23.6%	$4.6M+79.0%	$2.6M-90.9%	$28.3M+7.0%	$26.5M+7.0%	$24.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.6M-26.4%	$4.9M+218.1%	-$4.2M-28.2%	-$3.3M-361.9%	-$707K+97.4%	-$27.1M-6.1%	-$25.5M-6.2%	-$24.0M
Retained Earnings	-$53.7M-14.7%	-$46.8M-10.7%	-$42.3M-10.1%	-$38.4M-8.4%	-$35.4M-8.8%	-$32.6M-5.0%	-$31.0M-5.0%	-$29.5M

OSTX Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$14.2M-95.5%	-$7.3M-142.2%	-$3.0M
Capital Expenditures	$466K	N/A	N/A
Free Cash Flow	-$14.7M	N/A	N/A
Investing Cash Flow	-$466K	N/A	$1K
Financing Cash Flow	$9.4M-26.1%	$12.8M+344.7%	$2.9M
Dividends Paid	$2.0M	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$4.7M-99.4%	-$2.4M+31.4%	-$3.4M-44.9%	-$2.4M+29.8%	-$3.4M-284.1%	-$881K-37.3%	-$642K+26.3%	-$871K
Capital Expenditures	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$4.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0+100.0%	-$293K-68.6%	-$174K	N/A	N/A	N/A	N/A	$19
Financing Cash Flow	$3.8M+52.2%	$2.5M+135.9%	$1.1M-82.6%	$6.0M+17.5%	$5.1M+487.7%	$876K+24.6%	$703K-21.4%	$894K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OSTX Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A
Return on Assets	-420.4%-260.0pp	-160.4%+815.9pp	-976.3%
Current Ratio	0.03-1.2	1.20+1.2	0.03
Debt-to-Equity	-1.95+0.7	-2.70-1.7	-1.03
FCF Margin	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-189.1%-97.4pp	-91.8%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-76.8%-32.8pp	-44.0%+47.2pp	-91.2%	N/A	-145.4%-29.4pp	-116.0%+23.0pp	-139.1%	N/A
Current Ratio	0.56-0.5	1.03-0.1	1.16-0.0	1.20+0.4	0.76+0.7	0.050.0	0.040.0	0.03
Debt-to-Equity	1.17+0.4	0.72+2.7	-2.02+0.7	-2.70+1.1	-3.80-2.7	-1.050.0	-1.040.0	-1.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$6.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Beyondspring Inc BYSI

$70.9M

Immix Biopharma Inc IMMX

$473.5M

Adlai Nortye Ltd. ANL

$480.5M

Alterity Therapeutics Ltd ATHE

$64.4M

Adicet Bio Inc ACET

$67.1M

Frequently Asked Questions

Is OS THERAPIES INCORPORATED profitable?

No, OS THERAPIES INCORPORATED (OSTX) reported a net income of -$28.8M in fiscal year 2025.

What is OS THERAPIES INCORPORATED's EBITDA?

OS THERAPIES INCORPORATED (OSTX) had EBITDA of -$28.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is OS THERAPIES INCORPORATED's free cash flow?

OS THERAPIES INCORPORATED (OSTX) generated -$14.7M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is OS THERAPIES INCORPORATED's operating cash flow?

OS THERAPIES INCORPORATED (OSTX) generated -$14.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are OS THERAPIES INCORPORATED's total assets?

OS THERAPIES INCORPORATED (OSTX) had $6.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are OS THERAPIES INCORPORATED's capital expenditures?

OS THERAPIES INCORPORATED (OSTX) invested $466K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does OS THERAPIES INCORPORATED spend on research and development?

OS THERAPIES INCORPORATED (OSTX) invested $16.4M in research and development during fiscal year 2025.

How many shares does OS THERAPIES INCORPORATED have outstanding?

OS THERAPIES INCORPORATED (OSTX) had 40M shares outstanding as of fiscal year 2025.

What is OS THERAPIES INCORPORATED's current ratio?

OS THERAPIES INCORPORATED (OSTX) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is OS THERAPIES INCORPORATED's debt-to-equity ratio?

OS THERAPIES INCORPORATED (OSTX) had a debt-to-equity ratio of -1.95 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is OS THERAPIES INCORPORATED's return on assets (ROA)?

OS THERAPIES INCORPORATED (OSTX) had a return on assets of -420.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is OS THERAPIES INCORPORATED's cash runway?

Based on fiscal year 2025 data, OS THERAPIES INCORPORATED (OSTX) had $5.5M in cash against an annual operating cash burn of $14.2M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is OS THERAPIES INCORPORATED's debt-to-equity ratio negative or unusual?

OS THERAPIES INCORPORATED (OSTX) has negative shareholder equity of -$6.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is OS THERAPIES INCORPORATED's Piotroski F-Score?

OS THERAPIES INCORPORATED (OSTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are OS THERAPIES INCORPORATED's earnings high quality?

OS THERAPIES INCORPORATED (OSTX) has an earnings quality ratio of 0.50x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can OS THERAPIES INCORPORATED cover its interest payments?

OS THERAPIES INCORPORATED (OSTX) has an interest coverage ratio of -14.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.